Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis

Journal of Bone and Mineral Research

Volumn 12, Issue 10, 1997, Pages 1700-1707

  Khan, Sohail A ^a   Kanis, John A ^a   Vasikaran, Samuel ^a   Kline, W F ^b   Matuszewski, B K ^b   Mccloskey, Eugene V ^a   Beneton, Monique N C ^a   Gertz, Barry J ^b   Sciberras, David G ^b   Holland, S D ^b   Orgee, Jane ^a   Coombes, Gillian M ^a   Rogers, Suzanne R ^a   Porras, A G ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; HYDROXYPROLINE;

ADULT; AGED; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE MINERALIZATION; CLINICAL ARTICLE; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; OSTEOPOROSIS; POSTMENOPAUSE; URINARY EXCRETION;

AGED; ALENDRONATE; ALKALINE PHOSPHATASE; BONE DENSITY; CALCIUM; FEMALE; HALF-LIFE; HUMANS; HYDROXYPROLINE; INJECTIONS, INTRAVENOUS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE;

EID: 0030766092     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1997.12.10.1700     Document Type: Article

References (42)

1. Fleisch H 1989 Bisphosphonates: A new class of drugs in diseases of bone and calcium metabolism. Recent Results Cancer Res 116:1-28.
2. Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P 1983 Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 35:87-99.
3. Douglas DL, Russell RGG, Preston CJ, Preston FE, Duckworth T, Kanis JA, Prenton MA, Woodhead JS 1980 Effects of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet 1:1043-1047.
4. Kanis JA 1991 Pathophysiology and Treatment of Paget's Disease of Bone. Martin Dunitz, London, U.K.
5. Kanis JA 1995 Osteoporosis, revised Ed. Blackwell Science, Oxford, U.K.
6. Fleisch H 1995 Bisphosphonates in bone disease: From the laboratory to the patient, 2nd Ed. Parthenon Publishing Group, New York, NY, U.S.A.
7. 14C-clodronate in mice and rats. Pharmacol Toxicol 62:51-53.
8. Daley-Yates PT, Dodwell DJ, Pongchaidecha M, Coleman RE, Howell A 1991 The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. Calcif Tissue Int 49:433-435.
9. O'Rourke NP, McCloskey EV, Neugebauer G, Kanis JA 1994 Renal and nonrenal clearance of clodronate in patients with malignancy and renal impairment. Drug Invest 7:26-33.
10. Monkkonen J, Koponen H-M, Ytitalo P 1989 Comparison of the distribution of three bisphosphonates in mice. Pharmacol Toxicol 65:294-298.
11. Lin HJ, Duggan DE, Chen IW, Ellesworth RL 1991 Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos 19:926-932.
12. Conrad KA, Lee SM 1981 Clodronate kinetics and dynamics. Clin Pharmacol Ther 30:114-120.
13. Powell JH, DeMark BR 1985 Clinical pharmacokinetics of diphosphonates. In: Garattini S (ed.) Bone Resorption Metastases and Diphosphonates. Raven Press, New York, NY, U.S.A., pp. 41-49.
14. Pentikainen PJ, Elomaa I, Nurmi AK, Karkkainen S 1989 Pharmacokinetics of clodronate in patients with metastatic breast cancer. Int J Clin Pharmacol Ther 27:222-228.
15. Kanis JA, Melton LJ, Christianson C, Johston CC, Khaltaev N 1994a The diagnosis of osteoporosis. J Bone Miner Res 9: 1137-1141.
16. McCloskey EV, Spector TD, Eyres KS, Fern ED, O'Rourke N, Vasikaran S, Kanis JA 1993 The assessment of vertebral deformity: A method for use in population studies and clinical trials. Osteoporos Int 3:138-147.
17. Kline WF, Matuszewski BK 1992 Improved determination of the bisphosphonate alendronate in human plasma and urine by automated precolumn derivitization and high-performance liquid chromatography with fluorescence and electrochemical detection. J Chromatogr 583:183-193.
18. Udenfriend S 1960 A specific method for the analysis of hydroxyproline in tissues and urine. Ann Biochem 228:347-349.
19. Kanis JA, Yates AJP 1985 Measuring serum calcium. Br Med J 290:728-729.
20. Coulton LA, Preston CJ, Couch M, Kanis JA 1988 An evaluation of serum osteocalcin in Paget's disease and its response to diphosphonate treatment. Arthritis Rheum 31:1142-1148.
21. Clemens TL, Hendy GN, Papapoulos SE, Fraher LJ, Care AD, O'Riordan JLH 1979 Measurement of 1,25-dihydroxycholecalciferol in man by radioimmunoassay. Clin Endocrinol 11: 225-234.
22. Kanis JA, Heynen G, Cundy T, Cornet F, Patterson A, Russell RGG 1982 An estimate of the endogenous secretion rate of calcitonin in man. Clin Sci 63:145-152.
23. Lin HJ, Chen IW, Duggan DE 1992 Effect of dose, sex and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos 20:473-478.
24. Fogelman I, Bessant RG, Turner JF, Citrin DL, Boyce IT, Greig WR 1978 The whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone diseases. J Nucl Med 9:270-275.
25. Bisaz S, Jung A, Fleisch H 1978 Uptake by bone of pyrophosphate, diphosphonate and their technitium derivatives. Clin Sci Mol Med 54:265-272.
26. Fogelman I, Pearson DW, Bessant RG, Tofe AJ, Francis MD 1981 A comparison of skeletal uptake of three diphosphonates by whole body retention. J Nucl Med 22:880-883.
27. Sato M, Grasser W, Endo N, Akins R 1991 Bisphosphonate action: Alendronate localisation in rat bone and effects on osteoclast structure. J Clin Invest 88:2095-2105.
28. Kanis JA, Gertz BJ, Singer F, Ortolani S 1995 Rationale for the use of alendronate in osteoporosis. Osteoporos Int 5: 1-13.
29. Yakatan G, Poyner WJ, Talbert RL, Floyd BF, Slough CL, Ampulski RF, Benedict JJ 1982 Clodronate kinetics and bioavailability. Clin Pharmacol Ther 31:402-410.
30. Kanis JA, McCloskey EV, Sirtori P, Khan S, Fern D, Eyres K, Aaron J, Beneton MNC 1993 Rationale for the use of clodronate in osteoporosis. Osteoporos Int (Suppl 2):23-28.
31. Parfitt AM 1980 Morphological basis of bone mineral measurements: Transient and steady state effects of treatment in osteoporosis. Miner Electrolyte Metab 4:273-287.
32. Landman JO, Hamdy NAT, Pauwels EKJ, Papapoulos S 1995 Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. J Clin Endocrinol Metab 80:3465-3468.
33. McCloskey EV, Yates AJP, Beneton MNC, Galloway J, Harris S, Kanis JA 1987 Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone 8 (Suppl 1):35-42.
34. 3 increases serum levels of vitamin K-dependent bone protein. J Biol Chem 99:928-935.
35. Felix R, Fleisch H 1979 Increase in alkaline phosphatase activity in calvaria cells cultured with diphosphonates. J Biochem 183:73-81.
36. Vasikaran SD, McCloskey EV, Khan S, Kanis JA 1994 Intraindividual variation in fasting urinary calcium and hydroxyproline creatinine ratios measured in metabolic bone clinic patients as both outpatients and in patients. Ann Clin Biochem 31:272-276.
37. Gertz BJ, Kline WF, Matuszewski BK, Sacco JF, Lasseter KC, Porras AG 1991 Oral bioavailability and dose proportionality of alendronate (aminohydroxybutylidene bisphosphonate) in postmenopausal women. J Bone Miner Res 6 (Suppl 1):S281.
38. Garnero P, Shih WJ, Gineyts E, Kerpf DB, Delmas PD 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700.
39. Chesnut CH, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, Kher U, Pryor-Tillotson S, Santora AC 1995 Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodelling. Am J Med 99:144-152.
40. Harris ST, Gertz BJ, Eyre DR, Genant HK, Survill TT, Chestnut CH 1993 The effect of short-term treatment with alendronate upon vertebral density and biochemical markers of bone remodelling in early postmenopausal women. J Clin Endocrinol Metab 76:1399-1406.
41. Bickerstaff DR, O'Doherty DP, McCloskey EV, Hamdy NAT, Mian M, Kanis JA 1991 Effects of amino-butylidene diphosphonate in hypercalcaemia due to malignancy. Bone 12:17-20.
42. Kanis JA, O'Rourke N, McCloskey EV 1994b Consequence of neoplasia induced bone resorption and the use of clodronate (Review). Int J Oncol 5:713-731.